Provinces Continue to Close Gap Between Canadian and International Generic Drug Prices
The Patented Medicine Prices Review Board releases annual Generics360 report on generic drug pricing in Canada
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 02/09/16 -- Patented Medicine Prices Review Board
The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System (NPDUIS) research initiative, today published the most recent edition in a series of reports on generic drug pricing. Entitled Generics360, this comprehensive report compares generic drug prices in Canada with those of up to eleven other industrialized countries.
Provincial generic pricing policies, including those initiated by the pan-Canadian Pharmaceutical Alliance, achieved significant price reductions in Canada. While these declines exceeded the generic price reductions in foreign markets in recent years, prices of generic drugs remain appreciably higher in Canada than internationally.
Generics360 accounts for 81.9 percent of Canadian generic drug manufacturer sales and highlights major trends in generic drug pricing from a variety of perspectives, including reference brand-name prices, international generic-drug prices, and market size.
is available on the PMPRB website in PDF and accessible HTML formats.
Quick Facts
Related Products
- (Patented Medicine Prices Review Board)
Additional Links
- (Patented Medicine Prices Review Board)
Patented Medicine Prices Review Board
The Patented Medicine Prices Review Board is a respected public agency that makes a unique and valued contribution to sustainable spending on pharmaceuticals in Canada by:
About the NPDUIS initiative
The National Prescription Drug Utilization Information System (NPDUIS) is a research initiative established by federal, provincial, and territorial Ministers of Health in September 2001. It is a partnership between the Patented Medicine Prices Review Board and the Canadian Institute for Health Information (CIHI).
The NPDUIS initiative provides policy makers and public drug plan managers with critical analyses of price, utilization and cost trends so that Canada's health care system has more comprehensive and accurate information on how prescription drugs are being used and on sources of cost pressures.
The main data source for this report is IMS AG's MIDAS™ database.
Contacts:
Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.02.2016 - 17:30 Uhr
Sprache: Deutsch
News-ID 449640
Anzahl Zeichen: 0
contact information:
Town:
OTTAWA, ONTARIO
Kategorie:
Hospitals, Facilities and Providers
Diese Pressemitteilung wurde bisher 277 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Provinces Continue to Close Gap Between Canadian and International Generic Drug Prices"
steht unter der journalistisch-redaktionellen Verantwortung von
Patented Medicine Prices Review Board (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
